Dynamics of antibiotic resistant mycobacterium tuberculosis during long-term infection and antibiotic treatment

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Mariam, Solomon H ^a,b   Werngren, Jim ^a   Aronsson, Joakim ^c   Hoffner, Sven ^a   Andersson, Dan I ^c,d  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c RYHOV COUNTY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; PROTIONAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CASE REPORT; DISEASE DURATION; DYNAMICS; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MOLECULAR CLONING; MYCOBACTERIUM TUBERCULOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUBERCULOSIS; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANT TUBERCULOSIS; POLYMERASE CHAIN REACTION;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79959194083     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021147     Document Type: Article

References (54)

1. World Health Organization (2009) WHO Report 2009. Global tuberculosis control, surveillance, planning, financing. A Short Update to the 2009 Report.
2. Austin DJ, Kristinsson KG, Anderson RM, (1999) The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A 96: 1152-1156.
3. Lipsitch M, Samore MH, (2002) Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 8: 347-354.
4. Handel A, Margolis E, Levin BR, (2008) Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol 256: 655-662.
5. Gillespie SH, (2002) Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46: 267-274.
6. Cohen T, Murray M, (2004) Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10: 1117-1121.
7. Andersson DI, Hughes D, (2010) Antibiotic resistance and its costs: is it possible to reverse resistance? Nat Rev Microbiol 8: 260-271.
8. Zhang Y, Heym B, Allen B, Young D, Cole ST, (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358: 591-593.
9. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, et al. (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230.
10. Vilchèze C, Weisbrod TR, Chen B, Kremer L, Hazbon MH, et al. (2005) Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 49: 708-720.
11. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, et al. (1993) Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647-650.
12. Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, et al. (1997) The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 3: 567-570.
13. Scorpio A, Zhang Y, (1996) Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2: 662-667.
14. Finken M, Kirschner P, Meier A, Wrede A, Bottger EC, (1993) Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 9: 1239-1246.
15. Caminero JA, Sotgiu G, Zumla A, Migliori GB, (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10: 621-629.
16. Reynolds MG, (2000) Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156: 1471-1481.
17. Billington OJ, McHugh TD, Gillepie SH, (1999) Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43: 1866-1869.
18. Mariam DH, Mengistu Y, Hoffner SH, Andersson DI, (2004) Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 1289-1294.
19. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, et al. (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312: 1944-1946.
20. Björkman J, Hughes D, Andersson DI, (1998) Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci U S A 95: 3949-3953.
21. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI, (2000) Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287: 1479-1482.
22. vanSoolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, et al. (2000) Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 182: 1788-1790.
23. Pym AS, Saint-Joanis B, Cole ST, (2002) Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 70: 4955-4960.
24. Sander P, Springer B, Prammananan T, Strumfels A, Kappler M, et al. (2002) Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 46: 1204-1211.
25. Böttger EC, Springer B, (2008) Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr 167: 141-148.
26. Böttger EC, Springer B, Pletschette M, Sander P, (1998) Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 4: 1343-1344.
27. Lemey P, Rambaut A, Pybus OG, (2006) HIV evolutionary dynamics within and among hosts. AIDS Rev 8: 125-40.
28. Quiñones-Mateu ME, Arts EJ, (2006) Virus fitness: concept, quantification, and application to HIV population dynamics. Curr Top MicrobiolImmunol 299: 83-140.
29. Oliver A, Canton R, Campo P, Baquero F, Blazquez J, (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288: 1251-1254.
30. Wilder CN, Allada G, Schuster M, (2009) Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections. Infect Immun 12: 5631-5639.
31. Israel DA, Salama N, Krishna U, Rieger UM, Atherton JC, et al. (2001) Helicobacter pylori genetic diversity within the gastric niche of a single human host. Proc Natl Acad Sci U S A 98: 14625-14630.
32. Suerbaum S, Josenhans C, (2007) Helicobacter pylori evolution and phenotypic diversification in a changing host. Nat Rev Microbiol 5: 441-452.
33. Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D, (2002) Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 8: 843-849.
34. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN, (2002) Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 10: 45-52.
35. Kremer K, Glynn JR, Lillebaek T, Niemann S, Kurepina NE, et al. (2004) Definition of the Beijing/W Lineage of Mycobacterium tuberculosis on the Basis of genetic markers. J Clin Microbiol 42: 4040-4049.
36. Kamerbeek J, Schouls L, Kolk A, van Agtervveld M, van Soolingen D, et al. (1997) Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907-914.
37. vanEmbden JDA, Cave MD, Crawford JT, Dale JW, Eisenach KD, et al. (1993) Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31: 406-409.
38. Heym B, Alzari PM, Honore N, Cole ST, (1995) Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 15: 235-245.
39. vanDoorn HR, Kuijper EJ, van derEnde A, Welten AGA, van Soolingen D, et al. (2001) The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg→Leu mutation at codon 463 of katG are not associated. J Clin Microbiol 39: 1591-1594.
40. Ramaswamy SV, Amin AG, Goksel S, Stager CE, Dou S-J, et al. (2000) Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44: 326-336.
41. Goude R, Amin AG, Chatterjee D, Parish T, (2009) The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 53: 4138-4146.
42. Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, et al. (1998) A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 177: 1573-1581.
43. Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, et al. (1998) Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 1295-1297.
44. Melancon P, Lemieux C, Brakier-Gingras L, (1988) A mutation in the 530 loop of Escherichia coli 16S ribosomal RNA causes resistance to streptomycin. Nucl Acids Res 16: 9631-9639.
45. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, et al. (2010) Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 77: 830-840.
46. Meacci F, Orru G, Iona E, Giannoni F, Piersimoni C, et al. (2005) Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol 43: 3114-3120.
47. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, et al. (2003) Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 71: 7099-7108.
48. Nagaev I, Björkman J, Andersson DI, Hughes D, (2001) Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 40: 433-439.
49. Maisnier-Patin S, Berg OG, Liljas L, Andersson DI, (2002) Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol Microbiol 46: 355-366.
50. Sherman DR, Mdluli K, Hickey MJ, Arian TM, Morris SL, et al. (1996) Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272: 1641-1643.
51. Björkholm B, Sjölund M, Falk PG, Berg OG, Engstrand L, et al. (2001) Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc NatlAcadSci U S A 98: 14607-14612.
52. Hurdle JG, O'Neill AJ, Ingham E, Fishwick C, Chopra I, (2004) Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob Agents Chemother 48: 4366-4376.
53. vanRie A, Victor TC, Richardson M, Johnson R, van derSpuy GD, et al. (2005) Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 172: 636-642.
54. Shamputa IC, Jugheli L, Sadradze N, Willery E, Portaels F, et al. (2006) Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res 7: 99-109.